NCT06745219View on ClinicalTrials.gov

Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

July 30, 2025

Conditions
ThrombopeniaCervical CancerRadiotherapy Side EffectChemotherapeutic Toxicity
Interventions
DRUG

herombopag

receive harombopag for the prevention of thrombocytopenia in the next cycle of chemotherapy

Trial Locations (1)

1001042

Peking University Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER